Inicio Facebook Twitter Rss Agregar a Favoritos Contacto


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Artículos Destacados

Título: "Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials"

Autores: Mary-Ann Fitzcharles, Peter A. Ste-Marie, Winfried Häuser, Daniel J. Clauw, Shahin Jamal, Jacob Karsh, Tara Landry, Sharon Leclercq, Jason J. Mcdougall, Yoram Shir, Kam Shojania and Zach Walsh..

Arthritis Care & Research
Vol. 68, No. 5, May 2016, pp 681–688
DOI 10.1002/acr.22727
© 2016, American College of Rheumatology


To assess the efficacy, tolerability, and safety of cannabinoids (phyto- and syntheto-) in the management of rheumatic diseases.

Multiple databases, including Medline, Embase, and CENTRAL, were searched. Randomized controlled trials with outcomes of pain, sleep, quality of life, tolerability (dropouts due to adverse events), and safety (serious adverse events), with comparison of cannabinoids with any type of control, were included. Study methodology quality was evaluated with the Cochrane risk of bias tool.

In 4 short-term studies comprising 203 patients (58 with rheumatoid arthritis, 71 with fibromyalgia, and 74 with osteoarthritis [OA]), cannabinoids had a statistically significant effect on pain in 2, sleep in 2, and improved quality of life in 1, with the OA study prematurely terminated due to futility. The risk of bias was high for all 3 completed studies. Dizziness, cognitive problems, and drowsiness, as well as nausea, were reported for almost half of the patients. No serious adverse events were reported for cannabinoids during the study duration. No studies of herbal cannabis were identified.

Extremely small sample sizes, short study duration, heterogeneity of rheumatic conditions and products, and absence of studies of herbal cannabis allow for only limited conclusions for the effects of cannabinoids in rheumatic conditions. Pain relief and effect on sleep may have some potential therapeutic benefit, but with considerable mild to moderate adverse events. There is currently insufficient evidence to recommend cannabinoid treatments for management of rheumatic diseases pending further study.

Información Institucional . Servicios . Directorio de Socios . Actividades Científicas
Publicaciones . Investigación . Becas . Galería de Fotografías . Enlaces Relacionados
Desarrollado por:
Callao 384 Piso 2 Dto 6, CABA, Buenos Aires, Argentina. (C1022AAQ)
Tel: (+54 11) 4371-1759/1643